InMed Pharmaceuticals (INM) EBT (2021 - 2026)

InMed Pharmaceuticals has reported EBT for 6 years, with the latest figure at -$2.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 35.06% year-over-year to -$2.8 million; the trailing twelve-month figure through Mar 2026 stood at -$7.9 million (up 4.81% YoY), and the FY2025 full-year result was -$8.2 million, down 6.44% from the prior year.
• EBT for Q1 2026 stood at -$2.8 million, down from -$2.0 million in the prior quarter.
• The five-year high for EBT was -$336591.0 in Q2 2023, with the low at -$7.9 million in Q2 2022.
• Historically, EBT has averaged -$2.4 million across 5 years, with a median of -$2.0 million in 2025.
• Annual changes were most pronounced in 2023 — EBT jumped 95.72% — and 2024, when it tumbled 473.57%.
• InMed Pharmaceuticals' EBT stood at -$2.1 million in 2022, then advanced by 29.55% to -$1.5 million in 2023, then slumped by 74.2% to -$2.6 million in 2024, then advanced by 21.23% to -$2.0 million in 2025, then plunged by 37.65% to -$2.8 million in 2026.
• The last three EBT figures came in at -$2.8 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.7 million (Q3 2025), per Business Quant data.